01358nas a2200265   4500000000100000008004100001260001300042653002700055653002000082653002600102653001100128653001200139653002100151653003200172653002400204653002500228653001700253653003000270100001300300245003200313300001100345490000700356520071500363022001401078       2000                            d  c2000 Aug10aAdjuvants, Immunologic10aCancer Vaccines10aGTP Phosphohydrolases10aHumans10aleprosy10aMalaria Vaccines10aMerozoite Surface Protein 110aMycobacterium bovis10aRecombinant Proteins10aTuberculosis10aUrinary Bladder Neoplasms1 aYamada T00a[Study on recombinant BCG].  a517-200 v753 a<p>The progress of study on recombinant BCG was stated briefly. And then our studies on recombinant BCG were mentioned. Recombinant BCG secreting alpha antigen-fused merozoite surface protein 1 (MSP 1) was prepared and tested for its ability to control infections of Plasmodium yoelii. Result turned out it controlled the infection better than recombinant MSP 1 mixed with Freund incomplete adjuvant did. Recombinant BCG secreting excess amounts of antigen 85 complex A controlled infection of Mycobacterium leprae. Addition of recombinant BCG secreting alpha antigen-fused IL-2 to peritoneal exudate cells induced IFN-gamma resulting in killing bladder cancer cells more efficiently than parental BCG did.</p>  a0022-9776